Administration on Disabilities, The President's Committee for People With Intellectual Disabilities, 68161-68162 [2024-18942]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 164 / Friday, August 23, 2024 / Notices
to entry for Cloud Service
Providers(CSPs) with a focus on small
businesses, third party assessment
organizations (3PAOs), and small &
large agencies, and (2) identifying and
documenting ways to expedite the
authorization process for Cloud Service
Offerings (CSOs), such as exploring
agile authorizations and other potential
cost reductions, both labor and
financial, with a focus on small
businesses. Members of the public will
have the opportunity to provide oral
public comments during this meeting,
and may also submit public comments
in writing prior to this meeting by
completing the public comment form on
our website, https://gsa.gov/fscac. The
meeting agenda will be posted on
https://gsa.gov/fscac prior to the
meeting and can be accessed by
selecting the ‘‘Federal Secure Cloud
Advisory Committee meetings’’ tab on
the left, and then selecting the ‘‘October
10, 2024—Virtual’’ meeting accordion in
order to view all meeting materials,
agendas, and registration information.
khammond on DSKJM1Z7X2PROD with NOTICES
Meeting Attendance
Both of these virtual meetings are
open to the public. The meeting
materials, registration information, and
agendas for the meetings will be made
available prior to the meetings online at
https://gsa.gov/fscac, by selecting the
‘‘Federal Secure Cloud Advisory
Committee meetings’’ tab on the left,
and then selecting the ‘‘September 12,
2024—Virtual’’ meeting accordion or
‘‘October 10, 2024—Virtual’’ meeting
accordion. Registration for attending the
virtual meeting on Thursday, September
12, 2024, is highly encouraged by 5:00
p.m. EST, on Monday, September 9,
2024. Registration for attending the
virtual meeting on Thursday, October
10, 2024, is highly encouraged by 5:00
p.m. EST, on Monday, October 7, 2024.
After registration, individuals will
receive instructions on how to attend
the meeting via email.
For information on services for
individuals with disabilities, or to
request accommodation for a disability,
please email the FSCAC staff at
FSCAC@gsa.gov at least 10 days prior to
the meeting date. Live captioning may
be provided virtually.
Public Comment
Members of the public attending will
have the opportunity to provide oral
public comment during the FSCAC
meeting. Written public comments can
be submitted at any time by completing
the public comment form on our
website, https://gsa.gov/fscac, located
under the ‘‘Get Involved’’ section. All
written public comments will be
VerDate Sep<11>2014
17:23 Aug 22, 2024
Jkt 262001
provided to FSCAC members in advance
of the meeting if received by
Wednesday, September 4, 2024, for the
Thursday, September 12, 2024 meeting;
and by Wednesday, October 2, 2024, for
the Thursday, October 10, 2024 meeting,
respectively.
Margaret Dugan,
Service-Level Liaison, Federal Acquisition
Service, General Services Administration.
[FR Doc. 2024–18937 Filed 8–22–24; 8:45 am]
BILLING CODE 6820–34–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Community Living
Administration on Disabilities, The
President’s Committee for People With
Intellectual Disabilities
Administration for Community
Living, HHS.
ACTION: Notice.
AGENCY:
The President’s Committee
for People with Intellectual Disabilities
(PCPID) will host a meeting for its
members to discuss the 2024 PCPID
Report focused on Home and
Community Based Services (HCBS) and
discuss emerging issues facing people
with intellectual disabilities. All the
PCPID meetings, in any format, are open
to the public. Members of the public can
join in person or virtually. This meeting
will be conducted in presentation and
discussion format.
DATES: The meeting will take place on
Septmber 26, 2024 from 9:00 a.m. to
4:00 p.m. (EST) and September 27, 2024
from 9:00 a.m. to 3:00 p.m. (EST).
Comments received by September 13,
2024 will be shared with the PCPID at
the September 26–27, 2024 meeting.
ADDRESSES:
Comments: Comments and
suggestions may be shared through the
following ACL.gov link: https://acl.gov/
form/pcpid.
In Person/Webinar/Conference Call:
The meeting is open to the public and
will be hosted at the U.S. Department of
Health and Human Services on
September 26 and September 27, 2024.
The meeting will occur at the Switzer
Building Conference Room 1400 located
at 330 C Street SW, Washington, DC
20201. Members of the public can
observe the meeting in person or
virtually. To observe the meeting in
person, seating will be available for the
first 25 persons to reserve seats due to
space limitations. To participate in the
meeting virtually, the meeting will be
hosted on zoom meeting platform. In
SUMMARY:
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
68161
order to observe the proceedings in
person or virtually, you must register in
advance of the meeting at the following
link: https://us06web.zoom.us/meeting/
register/tZAlceGurzwj
H9FLdHPW7YZKOrs3l5GuCDnq.
FOR FURTHER INFORMATION CONTACT: Mr.
David Jones, Director, Office of
Intellectual Developmental Disabilities,
330 C Street SW, Switzer Building,
Room 1126, Washington, DC 20201.
Telephone: 202–795–7367. Fax: 202–
795–7334. Email: David.Jones@
acl.hhs.gov.
SUPPLEMENTARY INFORMATION:
Agenda: The Committee will discuss
the 2024 PCPID Report focused on
Home and Community Based Services
as it relates to the areas of direct support
professionals, employment, community
living, and Federal support programs.
And, the committee will begin to
examine emerging issues faced by
people with intellectual disabilities to
be addressed by the Committee. This
discussion will help develop a
framework for the preparation of the
2025 PCPID Report to the President.
Comments: Stakeholder input is very
important to the PCPID. Comments and
suggestions especially from people with
intellectual disabilities, are welcomed.
If there are comments related to HCBS
or other areas that you would like to
inform the PCPID, please share them
through the following ACL.gov link:
https://acl.gov/form/pcpid.
Background Information on the
Committee: The PCPID acts in an
advisory capacity to the President and
the Secretary of Health and Human
Services on a broad range of topics
relating to programs, services and
support for individuals with intellectual
disabilities. The function of PCPID is to:
(1) provide such advice concerning
intellectual disabilities as the President
or the Secretary of Health and Human
Services may request; and (2) provide
advice to the President and the
Secretary of Health and Human Services
to promote full participation of people
with intellectual disabilities in their
communities, such as: (A) expanding
educational opportunities; (B)
promoting housing opportunities; (C)
expanding opportunities for competitive
integrated employment; (D) improving
accessible transportation options; (E)
protecting rights and preventing abuse;
and (F) increasing access to assistive
and universally designed technologies;
and (3) provide advice to the President
and the Secretary of Health and Human
Services to help advance racial equity
and support for people with intellectual
disabilities within underserved
communities.
E:\FR\FM\23AUN1.SGM
23AUN1
68162
Federal Register / Vol. 89, No. 164 / Friday, August 23, 2024 / Notices
Statutory Authority: E.O. 14048, 85
FR 57313.
Dated: August 14, 2024.
Jennifer Johnson,
Acting Commissioner, Administration on
Disabilities.
[FR Doc. 2024–18942 Filed 8–22–24; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2007–D–0369]
Product-Specific Guidances; Draft and
Revised Draft Guidances for Industry;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of
additional draft and revised draft
product-specific guidances. The draft
guidances provide product-specific
recommendations on, among other
things, the design of bioequivalence
(BE) studies to support abbreviated new
drug applications (ANDAs). In the
Federal Register of June 11, 2010, FDA
announced the availability of a guidance
for industry entitled ‘‘Bioequivalence
Recommendations for Specific
Products’’ that explained the process
that would be used to make productspecific guidances available to the
public on FDA’s website. The draft
guidances identified in this notice were
developed using the process described
in that guidance.
DATES: Submit either electronic or
written comments on the draft guidance
by October 22, 2024 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
VerDate Sep<11>2014
17:23 Aug 22, 2024
Jkt 262001
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2007–D–0369 for ‘‘Product-Specific
Guidances; Draft and Revised Draft
Guidances for Industry.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of the draft guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993–
0002. Send one self-addressed adhesive
label to assist that office in processing
your requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the draft guidance document.
FOR FURTHER INFORMATION CONTACT:
Joseph Kotsybar, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 75, Rm. 3623A,
Silver Spring, MD 20993–0002, 240–
402–1062, PSG-Questions@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of June 11,
2010 (75 FR 33311), FDA announced the
availability of a guidance for industry
entitled ‘‘Bioequivalence
Recommendations for Specific
Products’’ that explained the process
that would be used to make productspecific guidances available to the
public on FDA’s website at https://
www.fda.gov/drugs/guidancecompliance-regulatory-information/
guidances-drugs.
As described in that guidance, FDA
adopted this process to develop and
disseminate product-specific guidances
and provide a meaningful opportunity
for the public to consider and comment
on those guidances. Under that process,
draft guidances are posted on FDA’s
website and announced periodically in
E:\FR\FM\23AUN1.SGM
23AUN1
]]>Agencies
[Federal Register Volume 89, Number 164 (Friday, August 23, 2024)]
[Notices]
[Pages 68161-68162]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-18942]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Community Living
Administration on Disabilities, The President's Committee for
People With Intellectual Disabilities
AGENCY: Administration for Community Living, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The President's Committee for People with Intellectual
Disabilities (PCPID) will host a meeting for its members to discuss the
2024 PCPID Report focused on Home and Community Based Services (HCBS)
and discuss emerging issues facing people with intellectual
disabilities. All the PCPID meetings, in any format, are open to the
public. Members of the public can join in person or virtually. This
meeting will be conducted in presentation and discussion format.
DATES: The meeting will take place on Septmber 26, 2024 from 9:00 a.m.
to 4:00 p.m. (EST) and September 27, 2024 from 9:00 a.m. to 3:00 p.m.
(EST).
Comments received by September 13, 2024 will be shared with the
PCPID at the September 26-27, 2024 meeting.
ADDRESSES:
Comments: Comments and suggestions may be shared through the
following ACL.gov link: https://acl.gov/form/pcpid.
In Person/Webinar/Conference Call: The meeting is open to the
public and will be hosted at the U.S. Department of Health and Human
Services on September 26 and September 27, 2024. The meeting will occur
at the Switzer Building Conference Room 1400 located at 330 C Street
SW, Washington, DC 20201. Members of the public can observe the meeting
in person or virtually. To observe the meeting in person, seating will
be available for the first 25 persons to reserve seats due to space
limitations. To participate in the meeting virtually, the meeting will
be hosted on zoom meeting platform. In order to observe the proceedings
in person or virtually, you must register in advance of the meeting at
the following link: https://us06web.zoom.us/meeting/register/tZAlceGurzwjH9FLdHPW7YZKOrs3l5GuCDnq.
FOR FURTHER INFORMATION CONTACT: Mr. David Jones, Director, Office of
Intellectual Developmental Disabilities, 330 C Street SW, Switzer
Building, Room 1126, Washington, DC 20201. Telephone: 202-795-7367.
Fax: 202-795-7334. Email: [email protected].
SUPPLEMENTARY INFORMATION:
Agenda: The Committee will discuss the 2024 PCPID Report focused on
Home and Community Based Services as it relates to the areas of direct
support professionals, employment, community living, and Federal
support programs. And, the committee will begin to examine emerging
issues faced by people with intellectual disabilities to be addressed
by the Committee. This discussion will help develop a framework for the
preparation of the 2025 PCPID Report to the President.
Comments: Stakeholder input is very important to the PCPID.
Comments and suggestions especially from people with intellectual
disabilities, are welcomed. If there are comments related to HCBS or
other areas that you would like to inform the PCPID, please share them
through the following ACL.gov link: https://acl.gov/form/pcpid.
Background Information on the Committee: The PCPID acts in an
advisory capacity to the President and the Secretary of Health and
Human Services on a broad range of topics relating to programs,
services and support for individuals with intellectual disabilities.
The function of PCPID is to: (1) provide such advice concerning
intellectual disabilities as the President or the Secretary of Health
and Human Services may request; and (2) provide advice to the President
and the Secretary of Health and Human Services to promote full
participation of people with intellectual disabilities in their
communities, such as: (A) expanding educational opportunities; (B)
promoting housing opportunities; (C) expanding opportunities for
competitive integrated employment; (D) improving accessible
transportation options; (E) protecting rights and preventing abuse; and
(F) increasing access to assistive and universally designed
technologies; and (3) provide advice to the President and the Secretary
of Health and Human Services to help advance racial equity and support
for people with intellectual disabilities within underserved
communities.
[[Page 68162]]
Statutory Authority: E.O. 14048, 85 FR 57313.
Dated: August 14, 2024.
Jennifer Johnson,
Acting Commissioner, Administration on Disabilities.
[FR Doc. 2024-18942 Filed 8-22-24; 8:45 am]
BILLING CODE 4154-01-P
